StockWatch
·

Laurus Labs Ltd

BSE: 540222

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
2.0K
+14.7%+27.8%
Expenditure
1.5K
+9.4%+16.3%
Net Profit
388.13
+33.9%+80.0%
OPM %
31.31%
+2.91pp+6.44pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00570.871.1K1.7K2.3KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Record quarter, but ₹3,000-Crore capex repricing shifts focus to execution

CDMO growth · capex intensity · peptide validation

Result verdictFollow-upQ2 FY2703 Nov 20266 minPharma & Healthcare

Record Q2 growth, but capex surge and Q3 softness cloud near-term

CDMO 86% growth · peptide validation · ₹3K capex raise

TranscriptDeep diveQ2 FY2703 Nov 20266 minPharma & Healthcare

Laurus Labs Q2 FY27: consolidated PAT up 124% YoY to ₹436 Cr as OPM expands to 34%

cdmo · margin expansion · operating leverage

ResultsQ2 FY2729 Oct 20263 minPharma & Healthcare
Latest
Board Meeting29 Oct, 3:01 pm

Laurus Labs Q2 FY27: consolidated PAT up 124% YoY to ₹436 Cr as OPM expands to 34%

Laurus Labs' consolidated PAT rose 124.3% YoY to ₹436.19 Cr (₹194.49 Cr in Q2 FY26) on revenue up 33.4% YoY to ₹2,206.37 Cr, and the print also builds sequentially — PAT +20.5% QoQ, revenue +8.9% QoQ over Q1 FY27's ₹362.07 Cr / ₹2,026.31 Cr. Consolidated is the primary basis here; standalone PAT grew a slower 80.0% YoY to ₹388.13 Cr (from ₹215.67 Cr) on 28.6% revenue growth, with the gap versus consolidated's 124.3% explained by subsidiary and non-controlling-interest contribution rather than any divergence in the core story. The margin expansion is the bigger story than topline: OPM (EBITDA/revenue) widened to roughly 34.0% from 24.4% a year ago and 31.5% last quarter, while NPM rose to 19.65% from 11.57% YoY and 17.79% QoQ. The bridge sits mainly in other expenses, which fell to ~17.0% of revenue from ~22.4% YoY, and in depreciation leverage (5.8% of revenue vs 7.3% YoY) as the base business scales — cost of materials consumed stayed roughly flat at ~41% of revenue, consistent with management's prior comment that raw-material headwinds persist. Management's July 2026 concall guided to 'margin sustainability despite raw material headwinds' and an ROCE climb from 19% toward a 25% target; this quarter's expansion goes well beyond mere sustainability, so the print reads as a beat against that qualitative bar, though ROCE itself isn't independently computable from this statement. No formal Street consensus for Q2 FY27 PAT/revenue turned up in search, and the company's own press release commentary on this result hasn't been extracted yet, so neither vs-Street nor management framing can be cross-checked beyond the filed numbers. Alongside the results, the board approved an interim dividend of ₹1.00/share (50% of the ₹2 face value, record date November 6, 2026) and the quarter also saw a ₹107.8 Cr investment in the 49%-held KRKA Pharma JV, consistent with the CDMO capacity push behind the FY27 capex guidance raised to ₹2,000 Cr from ₹1,500 Cr; H1 FY27 consolidated capex spend of ₹864.19 Cr is running well below half that revised full-year number so far. Going into Q3, the things to verify are whether the other-expense leverage holds as volumes scale further, whether capex execution catches up to the raised ₹2,000 Cr FY27 guidance, and whether CDMO mix disclosure starts showing progress toward the 50%-by-FY30 target.

29 Oct 2026, 03:01 pm

Corporate Events

DividendLAURUSLABS
2026
6Nov

₹1 / share

BSE Filing ↗
Board MeetingLAURUSLABS
2026
29Oct

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingLAURUSLABS
2026
24Jul

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingLAURUSLABS
2026
2Jul

Board Meeting

The Members of the Company at the 21st Annual General Meetin…

BSE Filing ↗
Board MeetingLAURUSLABS
2026
30Apr

Board Meeting

To consider and approve the audited financial results for th…

BSE Filing ↗
DividendLAURUSLABS
2025
24Apr

₹2 / share

BSE Filing ↗
DividendLAURUSLABS
2024
6Nov

₹0.4 / share

BSE Filing ↗
Board MeetingLAURUSLABS
2024
24Oct

Board Meeting

Consider and approve the Un-audited Financial Results of the…

BSE Filing ↗
DividendLAURUSLABS
2024
8May

₹0.4 / share

BSE Filing ↗
Board MeetingLAURUSLABS
2024
25Apr

Board Meeting

Consideration and approval of Audited Financial Results for …

BSE Filing ↗
Board MeetingLAURUSLABS
2024
24Jan

Board Meeting

Consider and approve unsigned financial results for the quar…

BSE Filing ↗
DividendLAURUSLABS
2023
30Oct

₹0.4 / share

BSE Filing ↗
Board MeetingLAURUSLABS
2023
20Oct

Board Meeting

consider and approve Un-Audited Financial Results of the Com…

BSE Filing ↗